

### Creating a Unique Surfactants Portfolio Connected by Chemistry

7<sup>th</sup> April 2022



### Disclaimer

This presentation contains "forward-looking statements" of Indorama Ventures Public Company Limited (the "Company") that relate to future events, which are, by their nature, subject to significant risks and uncertainties. All statements, other than statements of historical fact contained herein, including, without limitation, those regarding the future financial position and results of operations, strategy, plans, objectives, goals and targets, future developments in the markets where the Company participates or is seeking to participate and any statements preceded by, followed by or that include the words "target", "believe", "expect", "aim", "intend", "will", "may", "anticipate", "would", "plan", "could", "should, "predict", "project", "estimate", "foresee", "forecast", "seek" or similar words or expressions are "forward-looking statements".

Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future and are not a guarantee of future performance.

Such forward-looking statements speak only as at the date of this presentation, and the Company does not undertake any duty or obligation to supplement, amend, update or revise any such statements. The Company does not make any representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved.

The Company makes no representation whatsoever about the opinion or statements of any analyst or other third party. The Company does not monitor or control the content of third party opinions or statements and does not endorse or accept any responsibility for the content or the use of any such opinion or statement.

Please note that this presentation has been normalized for the Lake Charles, Louisiana Ethylene Cracker (IVOL) till end of 2021. Starting late July 2021 IVOL was under commissioning and started up in November 2021. In order to make a fair assessment and analysis of our operating assets, management feels it appropriate to move IVOL P&L values below EBITDA as extraordinary items including historical periods till end of 2021.



### Key leaders joining today



CEO & CFO of Indorama Ventures



**Executive President of IOD** 



CEO of IOD South America





### IVL IOD + Oxiteno | Creating an industry leader in Surfactants



- Largest Surfactants producer in LATAM
- Integrated into EO and Natural Fatty Alcohols
- Strong innovation and close customer relationships
- Sustainable solutions focused with 35% of products containing renewable ingredients



- · Extends technology & end markets
- Integrates into natural based feedstocks and accelerates innovation engine
- Expands geographical presence
- Will leverage IOD's operational excellence and large asset base



- Enterprise value of US\$1.3B and 6.1x1 EV/EBITDA on 2021 results
- Total synergies of ~\$100M targeted
- Fully financed by free cash flows, working capital assets, interest-bearing debts, and deferred payment of US\$150M to 2Q24



# Oxiteno | The leading LATAM Surfactants solutions provider with access to bio-based feedstocks

#### **Business Overview**



- #1 Surfactants producer in LATAM
- Sole producer of EO in South America
- Sole producer of Natural Fatty Alcohols in LATAM



Serves highly attractive emerging markets



HVA products, attractive end-markets including crop solutions, HPC and coatings



- High degree of customer intimacy



- Best-in-class R&D capabilities
- Robust sustainable product innovation unit



COMA from new products



New colleagues




Target synergies




R&D and Tech. Centers


Note: (1) Adjusted based on IVL accounting methodology by reversing catalyst amortization to below EBITDA. Source: Oxiteno Management. IVL Analysis

#### 2021 Business Split





#### LATAM EBITDA<sup>1</sup> (\$M)






### The combination creates unique proposition for customers

### Americas Nonionic Surfactants Capacity<sup>1</sup>

#### IVL IOD + Oxiteno Int. Downstream Footprint<sup>2</sup>



Note: (1) As of 2021, includes ethoxylates and PEG; (2) Combined Downstream 2021 revenue includes Surfactants, PO/PG, EOA, LAB, Purified EO and others; Oxiteno financials exclude Pasadena

Source: Woodmac, Oxiteno Management, IVL Analysis

#### Combined Int. Downstream Overview



\$2.7B Revenue<sup>2</sup>



**18** Industrial Units NA, SA, and APAC




11 R&D & Tech Centers NA, SA, Europe, and APAC



1,000+ Products Sold




### Oxiteno means significant leap forward towards specialty surfactants





# Oxiteno meaningfully increases the Surfactants portfolio, including strong capabilities to support the combined IOD business

#### Oxiteno increases Int. Downstream<sup>1</sup> EBITDA



## Oxiteno brings strong HVA capabilities to IOD



Customer-centric application development and technical services



Robust and rigorously managed innovation pipeline



Well established product management function and pricing practices



Sophisticated **customer segmentation** methodology

Note: (1) IOD Int. Downstream includes Surfactants, PO/PG, EOA, LAB, Purified EO and others; ethylene (Upstream) allocated to Downstream and Intermediates portfolio based on consumptions to reflect integrated performance; Oxiteno Int. Downstream includes Surfactants, Purified EO, EOA, Oleochemicals, Solvents, exclude Pasadena financials
Source: IVL Analysis, Oxiteno Management



# Oxiteno increases the portion of the portfolio delivering higher relative margins and extends IOD's reach to more downstream applications



Note: (1) Int. Downstream includes Surfactants, PO/PG, EOA/LAB, Purified EO and others; Int. Intermediates includes MEG and MTBE; ethylene (Upstream) allocated to Downstream and Intermediates portfolio based on consumptions to reflect integrated performance, Oxiteno financials excludes Pasadena

Source: IVL Analysis, Oxiteno Management



# Strong synergy levers identified, accelerated through pre-close Clean Team approach

#### **Revenue Synergies**



#### Cross-Sell

Identify the most attractive opportunities to expand across customer base



#### Product-Asset Decisions

Examine combined asset capabilities and portfolios to unlock value



#### Vertical Integration

Identify where molecules can be consumed captively / further formulated downstream



#### **Innovation Pipeline**

Leverage unified R&D to accelerate into sustainable solutions & high growth offerings



#### **Contract Harmonization**

Identify harmonization / improvement opportunities for shared customers

#### **Cost Synergies**



#### **Direct Procurement**

Leverage combined procurement best practices and raw material volume



#### Indirect Procurement

Replicate IOD Indirect Procurement initiatives across combined portfolio assets



#### SG&A (excl. R&D)

Focused fixed cost review and leverage IVL support services infrastructure



#### Operations

Instill best practices to drive best-in-class operations spend & advance digital maturity



#### **Supply Chain Optimization**

Optimize combined footprint to improve customer centricity

Project Olympus – well-tested processes and tools to ensure delivery of **\$100M of synergies** 



# Working through a Clean Team, we have built more tactical initiatives as well as strategic opportunities to drive commercial value levers

**COMA Synergy Levers** 

Tactical Opportunities Ready for Day 1

Strategic Recommendations (6 - 18 mon)



Cross-Sell



**Product-Asset Decisions** 



Vertical Integration



**Innovation Pipeline** 



**Contract Harmonization** 

Specific customer level cross-sell charters validated by sales teams

Action plan to increase capacity utilization through optimization within and between production locations across combined asset footprint e.g. utilization of Pasadena assets

Value potential and make/buy decision frameworks for vertical integration opportunities

Overlapping R&D / application developments that can be accelerated / re-allocated

Harmonization of **contract terms** for overlapping customers

Portfolio-wide pricing & innovation process transference (best of both approach)

Optimization of account <u>coverage</u>, <u>channel strategy</u>, <u>and customer</u> <u>service-levels</u>

Product and end-market <u>adjacency</u> opportunities



# Proactive in pre-close planning for successful integration and accelerate value creation



Organization for executive levels completed with reporting structure identified



Day 1 through 100+ functional integration maps developed (with strong coordination of 150+ people)



Revenue synergy roadmap developed through a Clean Team to accelerate value recognition



Identified manufacturing asset optimization opportunities through Clean Team



# Oxiteno positions IOD Int. Downstream as a Surfactants industry leader and expands IVL sustainability and innovation platforms





#### Value addition to IOD

- Increases footprint diversification to 40% outside the US
- Increases IOD Core EBITDA by 58% through market expansion, technology, and portfolio
- Enhances market backed innovation model, expanding the pipeline by 2.5x

#### Value addition to IVL

- Revenue growth of \$1.2B at 19% EBITDA Margin
- Enhances IVL Core EBITDA by 13% from \$1.7B
- Adds sustainable product innovation, with ~35% of Oxiteno products containing renewable ingredients






## **Appendix**





# IVL's repeatable growth playbook to continue building IOD into a global leader in sustainable surfactants



# Combination creates an integrated portfolio serving both high volume and high value Surfactants market

#### **IVL IOD Winning Formula** Vertical Earnings resiliency through raw material cost integration advantage Balanced portfolio Enhanced proportion of high value add to integrated volume business, creating unique competitiveness Tailored go-to-market model Increasing volume and margins Enhance innovation engine and global through capability innovation






Source: IVL Analysis

INDORAMA


### IOD Downstream vertical serves attractive, high-growth end markets



Note: 2018 global surfactants market size; 2. CAGR 18-24 Source: IHS




IVOX Int. Downstream performance improved on the back of market tailwind and Project Olympus delivery. Int. Intermediate suffered from market downturn but partially mitigated through Project Olympus



#### Benefitting from Project Olympus delivery

#### **Project Olympus 2021**



Target Delivery

\$169M by 2023

#### **Operational Excellence**

- Yield improvement
- Asset utilization

#### **Procurement & Supply Chain**

- Logistics savings
- Direct procurement
- Energy & Utilities cost savings
- Maintenance

#### Sales Excellence

Commercial excellence

#### Organize for Performance

- Fixed cost

Digitalization

Note: (1) US Int. MEG spread = ICIS MEG ASP = (0.58 x 0.422 x 22.046 x IHS US Ethane price (cpg)); (2) US MTBE Spreads = Platts US MTBE = (IHS US N-Butane in cpg + 0.35\*IHS US Spot Methanol in cpg)\*3.55; (3) Excluding IVOL

Source: IVL Analysis



### Harness the combined North American asset footprint to its full potential

#### Combined IOD & Oxiteno NAM Footprint





Note: EO/PO pull through based on estimated volume (55% EO pull through & 25% PO pull through) Source: IVL analysis, Oxiteno management

#### Value Creation in Marketing

- Leverage Oxiteno's & IVL's portfolio through each other's commercial access in North America, Europe and APAC
- Leverage techno-commercial setup across the globe

#### **Asset Footprint Network Capabilities**

- Leverage the power of 4 + 4 = 8 manufacturing assets in Mexico and USA to establish best possible combination of Volume and Value based product footprint
- With captive feedstocks from PNO to Oxiteno USA, develop PO led product portfolio and benefit from EO supply
- Improve Oxiteno USA's production reliability and maintenance standards benchmarking to IVL IOD sites
- Leverage on combined R&D capabilities to fully utilize the 8 assets
- Combined best practices

#### **Operational Excellence**

- Optimize supply chain cost by leveraging feedstock and product movement across assets and markets
- Optimize variable cost by leveraging purchasing through combined scale
- Leverage IVL's ongoing transformation program

